CARLSBAD, Calif.--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for serious neurological ...

Positive RG6501 (OpRegen®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for ...

Interested parties may access the conference call on August 12, 2025, by dialing (800) 715-9871 from the U.S. and Canada and should request the “Lineage Cell Therapeutics Call”. A live webcast of the ...

At Lineage Cell Therapeutics, CEO Brian Culley has been working for many years on allogeneic cell therapies across a range of ...

Lineage Cell Therapeutics (AMEX:LCTX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below offers a condensed ...

According to a regulatory filing, as previously reported, in December 2021, Lineage Cell Therapeutics (LCTX) entered into a collaboration and license agreement with Genentech, Inc. and Roche (RHHBY) ...

Lineage Cell Therapeutics, Inc. ((LCTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Lineage Cell Therapeutics Faces Mixed Sentiments Amidst Progress and Financial ...

In this article, we will be taking a look at the 15 Best Biotech Penny Stocks to Invest in Right Now. Lineage Cell Therapeutics, Inc. is one of them. Lineage Cell Therapeutics, Inc. (NYSE:LCTX) is a ...

Russo Partners – Media Relations Nic Johnson or David Schull ([email protected]) ([email protected]) (212) 845-4242 Source: Lineage Cell Therapeutics, Inc. The views and ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...